OTC Prilosec Risk/Benefit Ratio Relative To Current OTCs Questioned By Andrx
This article was originally published in The Tan Sheet
Executive Summary
Uncertainties about the safety and efficacy of OTC Prilosec (omeprazole 20 mg) combined with "the relative effectiveness" of currently available nonprescription acid-reducers, should cause FDA to deny Procter & Gamble/AstraZeneca's switch NDA, Andrx says in a Nov. 20 citizen petition